- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Socinski on Nivolumab in NSCLC
Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).
Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).
The randomized Checkmate-057 trial examined patients in the second-line setting of advanced nonsquamous non-small cell lung cancer. Patients were randomized to docetaxel at the approved dosage or nivolumab bi-weekly. The primary endpoint was overall survival. The trial ended early due to demonstrated superiority for nivolumab over docetaxel, with a three-month difference in median survival and a statistically significant hazard ratio. The study also showed a benefit in response rate.
Socinski says there was no advantage in PFS between the two arms. In the median PFS, docetaxel was favored over nivolumab. However, the one-year PFS rate was twice favorable for nivolumab compared to docetaxel.
<<<